Press Releases

Diamyd Medical’s financial year comprises 1 September – 31 August.

Data pager

1 2 3

Show:

PageSizeComboBox
	select

3 pages

Data pager

1 2 3

Show:

PageSizeComboBox
	select

3 pages

4/30/2025

Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million

4/29/2025

Diamyd Medical’s rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million

4/28/2025

Last day of the subscription period in Diamyd Medicals rights issue

4/28/2025

Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes

4/25/2025

Diamyd Medical’s pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026

4/22/2025

Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue

4/21/2025

Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout

4/17/2025

The prevention trial DiaPrecise with Diamyd^® clears first safety milestone

4/15/2025

Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment

4/14/2025

Diamyd Medical publishes prospectus with regards to the rights issue

Order GAD for preclinical research

ORDER

©

Privacy Policy | Cookie Policy | Expanded Access Policy

Share This Page

GAD PRODUCTS

Order GAD for preclinical research